No Detail Found!

Comparison of three standard neoadjuvant chemotherapy regimens based on pathological tumor response in breast cancer patients

Author(s)
Jamshed Ali Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre,Peshawar,Pakistan
Iqra Malik Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre,Peshawar,Pakistan
Muhammad Shah Fahad Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre,Peshawar,Pakistan
Ayesha Rahat Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre,Peshawar,Pakistan
Shameen Ikram Department of Pharmacy, Shaukat Khanum Hospital and Trust,Peshawar,Pakistan
Neelam Siddiqui Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre,Lahore,Pakistan
Abstract
We compared the efficacy of different neoadjuvant chemotherapy regimens and pathological factors related to higher pCR in localized breast cancer. This comparative retrospective study included 313 patients with breast carcinoma who received neoadjuvant therapy from January 2017 till July 31, 2019 at our institute. Patients were grouped in 3 different categories according to the treatment arms. In Arm A, patients received dose-dense AC [4 Cycles] followed by dose dense paclitaxel [4 Cycles]. In Arm B, 2 weekly dose dense AC [4 Cycles] followed-by paclitaxel every week [12 Cycles], while Arm C received 3 weekly AC [4 Cycles] and 3 weekly paclitaxel [4 Cycles]. pCR was seen in 135(43.1%) patients with the highest pCR in arm B i-e 33(55%), followed by 39(43.3%) in arm A, and 63(38.6%) in arm C. Triple-negative patients had the highest percentage of pCR 38 (65.5%). HER2 positive patients who received neoadjuvant Trastuzumab also had increased pCR rate of 21 (61.7%). ER/PR positive, HER2 negative patients had the lowest pCR 56 (33.5%). Dose dense AC [4 cycles] followed-by weekly Paclitaxel [12 cycles] is the most effective neoadjuvant therapy regimen for breast cancer patients, particularly if they were also triple negative and HER2 positive receiving Trastuzumab.
Publication Details
Page(s) 129-133
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Breast Cancer, Neoadjuvant therapy, Trastuzumab
References
Carey LA,Dees EC,Sawyer L,Gatti L,Moore DT,Collichio F,Ollila DW,Sartor CI,Graham ML,Perou CM .2007 .The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res., 13(8) : 2329-2334.
Carey LA,Metzger R,Dees EC,Collichio F,Sartor CI,Ollila DW,Klauber-DeMore N,Halle J,Sawyer L,Moore DT,Graham ML .2005 .American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J. Natl. Cancer Inst., 97(15) : 1137-1142.
Catane R,Kaufman B,Zach L,Wolf I,Gluck I,Barsuk T,Modiano D,Shabtai M,Papa M,Paluch-Shimon S .2005 .Dose-dense neoadjuvant chemotherapy in breast cancer. Am. J. Clin. Oncol., 23(16) : 807-807.
Chen JH,Bahri S,Mehta RS,Kuzucan A,Yu HJ,Carpenter PM,Feig SA,Lin M,Hsiang DJB,Lane KT,Butler JA,Nalcioglu O,Su MY .2011 .Breast cancer: Evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology, 261(3) : 735-43.
Chou HH,Kuo WL,Yu CC,Tsai HP,Shen SC,Chu CH,Yu MC,Lo YF,Dabora MA,Chang HK,Lin YC,Ueng SH,Chen SC .2019 .Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. , 42(1) : 66-74.
Cortazar P,Zhang L,Untch M,Mehta K,Costantino JP,Wolmark N,Bonnefoi H,Cameron D,Gianni L,Valagussa P,Swain SM,Prowell T,Loibl S,Wickerham DL,Bogaerts J,Baselga J,Perou C,Blumenthal G,Blohmer J,Von Minckwitz G .2014 .Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. The Lancet, 384(9938) : 164-172.
Gianni L,Eiermann W,Semiglazov V,Manikhas A,Lluch A,Tjulandin S,Zambetti M,Vazquez F,Byakhow M,Lichinitser M,Climent MA,Ciruelos E,Ojeda B,Mansutti M,Bozhok A,Baronio R,Feyereislova A,Barton C,Valagussa P,Baselga J .2010 .Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER. The Lancet. , 375(9712) : 377-384.
Gradishar WJ,Anderson BO,Abraham J,Aft R,Agnese D,Allison KH,Blair SL,Harold Burstein J,Dang C,Elias AD,Giordano SH,Matthew Goetz P,Steven Goldstein J,Krishnamurthy Isakoff J,Kumar R Isakoff J,Natl J. .2020 .Nccn Clinical Practice Guidelines In: Oncology. , 18(4) : 452-478.
Houssami N,MacAskill P,von Minckwitz G,Marinovich ML,Mamounas E .2012 .Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur. J. Cancer, 48(18) : 3342-3354.
Huang M,Zhao J,Haiderali A,Cortés J,Ramsey SD,Briggs A,Hu P,Karantza V,Aktan G,Qi CZ,Gu C,Xie J,Yuan M,Cook J,Untch M,Schmid P,Fasching PA .2020 .Association of pathological complete response with long-term survival outcomes in triple-negative breast cancer: A meta-analysis. Cancer Res., 80(24) : 5427-5434.
Huober J,von Minckwitz G,Denkert C,Tesch H,Weiss E,Zahm DM,Belau A,Khandan F,Hauschild M,Thomssen C,Hogel B,Darb-Esfahani S,Mehta K,Loibl S K .2010 .Effect of neoadjuvant anthracyclinetaxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the gepar trio study. Breast Cancer Res. Treat., 124(1) : 133-140.
Katayama A,Miligy IM,Shiino S,Toss MS,Eldib K,Kurozumi S,Quinn CM,Badr N,Murray C,Provenzano E,Callagy G,Martyn C,Millican-Slater R,Purdie C,Purnell D,Pinder SE,Oyama T,Shaaban A M,Ellis I,Rakha EA .2021 .Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology, 34 : 1271-1281.
Kaufmann M,Hortobagyi GN,Goldhirsch A,Scholl S,Makris A,Valagussa P,Blohmer JU,Eiermann W,Jackesz R,Jonat W,Lebeau A,Loibl S,Miller W,Seeber S,Semiglazov V,Smith R,Souchon R,Stearns V,Untch M .2006 .Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. In: J. Clin. Oncol., 24(12) : 1940-1949.
Liedtke C,Mazouni C,Hess KR,André F,Tordai A,Mejia JA,Gonzalez-Angulo WF,Hennessy AM,Green B,Cristofanilli M,Hortobagyi M,Pusztai L GN .2008 .Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol., 26(8) : 1275-1281.
Petrelli F,Coinu A,Lonati V,Cabiddu M,Ghilardi M,Borgonovo K,Barni S K .2016 .Neoadjuvant dosedense chemotherapy for locally advanced breast cancer: A meta-analysis of published studies. AntiCancer Drugs, 27(7) : 702-708.
Soomro Rufina,Mamshad Rufina .2018 .Age and stage of breast cancer in Pakistan: An experience at a tertiary care center. J. Pak. Med, 68(11) : 1682-1685.
Sasanpour P,Sandoughdaran S,Mosavi-Jarrahi A,Malekzadeh M. .2018 .Predictors of pathological complete response to neoadjuvant chemotherapy in Iranian breast cancer patients. Asian Pac. J. Cancer Prev, 19(9) : 2423-2427.
Untch M and Von Minckwitz G .2011 .Neoadjuvant chemotherapy: Early response as a guide for further treatment: Clinical, radiological, and biological. J Natl Cancer Inst Monogr, 43 : 138-41.
Wu K,Yang Q,Liu Y,Wu A,Yang Z .2014 .Metaanalysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J. Surg Oncol, 12 : 95.
0

Citations

0

Downloads

139

Views